Arnau Antolí

6.1k total citations
9 papers, 125 citations indexed

About

Arnau Antolí is a scholar working on Infectious Diseases, Immunology and Neurology. According to data from OpenAlex, Arnau Antolí has authored 9 papers receiving a total of 125 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 4 papers in Immunology and 2 papers in Neurology. Recurrent topics in Arnau Antolí's work include COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and Respiratory viral infections research (2 papers). Arnau Antolí is often cited by papers focused on COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and Respiratory viral infections research (2 papers). Arnau Antolí collaborates with scholars based in Spain and Netherlands. Arnau Antolí's co-authors include Xavier Solanich, Gemma Rocamora-Blanch, Xavier Corbella, Joan Sabater‐Riera, Antoni Riera‐Mestre, Alexander Hoischen, Manel Esteller, Frank L. van de Veerdonk, Simon V. van Reijmersdal and Jesús Del Valle and has published in prestigious journals such as Clinical Infectious Diseases, Frontiers in Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Arnau Antolí

8 papers receiving 125 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arnau Antolí Spain 5 94 57 25 21 16 9 125
Gemma Rocamora-Blanch Spain 4 81 0.9× 54 0.9× 23 0.9× 18 0.9× 9 0.6× 5 107
Amalia Tejeda Velarde Spain 6 63 0.7× 95 1.7× 28 1.1× 30 1.4× 18 1.1× 24 168
Parni Nijhawan Italy 5 66 0.7× 34 0.6× 17 0.7× 21 1.0× 32 2.0× 8 117
Sydney Stein United States 6 52 0.6× 42 0.7× 18 0.7× 43 2.0× 11 0.7× 9 139
Krystallenia Paniskaki Germany 5 108 1.1× 30 0.5× 17 0.7× 14 0.7× 51 3.2× 11 140
Mary Arnaud‐Arnould France 3 89 0.9× 78 1.4× 22 0.9× 44 2.1× 21 1.3× 3 146
Journey Cole United States 5 74 0.8× 47 0.8× 31 1.2× 28 1.3× 20 1.3× 7 126
Sara Falck‐Jones Sweden 5 54 0.6× 77 1.4× 23 0.9× 8 0.4× 16 1.0× 7 116
Juan Francisco Gutiérrez‐Bautista Spain 7 93 1.0× 36 0.6× 17 0.7× 27 1.3× 32 2.0× 17 143
Hannes Axelsson Sweden 5 135 1.4× 77 1.4× 16 0.6× 31 1.5× 37 2.3× 6 220

Countries citing papers authored by Arnau Antolí

Since Specialization
Citations

This map shows the geographic impact of Arnau Antolí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnau Antolí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnau Antolí more than expected).

Fields of papers citing papers by Arnau Antolí

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnau Antolí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnau Antolí. The network helps show where Arnau Antolí may publish in the future.

Co-authorship network of co-authors of Arnau Antolí

This figure shows the co-authorship network connecting the top 25 collaborators of Arnau Antolí. A scholar is included among the top collaborators of Arnau Antolí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnau Antolí. Arnau Antolí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Antolí, Arnau, Paula Rofes, Gemma Rocamora-Blanch, et al.. (2025). Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients. Clinical Immunology. 276. 110491–110491. 1 indexed citations
2.
Morandeira, Francisco, et al.. (2025). Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients. Frontiers in Immunology. 16. 1556731–1556731. 1 indexed citations
3.
Antolí, Arnau, Gardenia Vargas‐Parra, Paula Rofes, et al.. (2025). From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 Severity. Journal of Clinical Immunology. 45(1). 100–100. 1 indexed citations
4.
Llopis, Ferrán, Aurema Otero, Javier Jacob, et al.. (2023). Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial. Clinical Infectious Diseases. 76(10). 1784–1792. 6 indexed citations
5.
Antolí, Arnau, Gemma Rocamora-Blanch, Sergio Martínez‐Yélamos, et al.. (2022). Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. Frontiers in Immunology. 13. 895209–895209. 17 indexed citations
6.
Solanich, Xavier, Gardenia Vargas‐Parra, Caspar I. van der Made, et al.. (2021). Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. Frontiers in Immunology. 12. 719115–719115. 74 indexed citations
7.
Solanich, Xavier, Arnau Antolí, Núria Padullés Zamora, et al.. (2021). Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol. Contemporary Clinical Trials Communications. 21. 100716–100716. 13 indexed citations
8.
Antolí, Arnau, et al.. (2021). OP0004 AUTOIMMUNE AND INFLAMMATORY MANIFESTATIONS IN COMMON VARIABLE IMMUNODEFICIENCY DISORDERS. Annals of the Rheumatic Diseases. 80. 1–2.
9.
Solanich, Xavier, Miguel Fernández-Huerta, Arnau Antolí, et al.. (2021). Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. Journal of Clinical Medicine. 10(5). 918–918. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gemma Rocamora-Blanch Breakdown of academic impact, for papers by Amalia Tejeda Velarde Breakdown of academic impact, for papers by Parni Nijhawan Breakdown of academic impact, for papers by Sydney Stein Breakdown of academic impact, for papers by Krystallenia Paniskaki Breakdown of academic impact, for papers by Mary Arnaud‐Arnould Breakdown of academic impact, for papers by Journey Cole Breakdown of academic impact, for papers by Sara Falck‐Jones Breakdown of academic impact, for papers by Juan Francisco Gutiérrez‐Bautista Breakdown of academic impact, for papers by Hannes Axelsson
Rankless by CCL
2026